SEC Filings
State Street Holds 6.6% Of PTC Therapeutics In Passive Position
The holding covered 5,512,555 shares as of September 30, with State Street certifying it was not seeking to influence control.
PTC Therapeutics (PTCT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The holding covered 5,512,555 shares as of September 30, with State Street certifying it was not seeking to influence control.
SEC Filings
The rare-disease drugmaker's board approved the repurchase program days after it raised its 2026 revenue guidance.
Earnings
CEO Matthew Klein pointed to low-20% cumulative discontinuations and internal data as outside prescription trackers drew scrutiny.
Earnings
Raised 2026 guidance of $960 million to $990 million in product revenue leans on Sephience, while Emflaza faces generic pricing.
SEC Filings
A July decision to settle in cash drove a debt loss, and the quarter also carried a $111.0 million expense for a Fabry gene therapy.
Earnings
The rare-disease drugmaker posted a $51.7 million quarterly net loss after booking $111.0 million for a Fabry gene therapy it bought.